CXCL9 and pancreatic neoplasm: Moreover, it is possible that PD-L1 activities are connected to chemokine-related pathways also in other aspects, as evidenced by the association of PD-L1 with the chemokine CXCL9 in basal patients [86] and by the cooperativity between CXCR4 (CXCL12 receptor) and PD-L1 inhibitors in pancreatic cancer [87].